363 related articles for article (PubMed ID: 30755732)
1. Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model.
Alessandrini F; Menotti L; Avitabile E; Appolloni I; Ceresa D; Marubbi D; Campadelli-Fiume G; Malatesta P
Oncogene; 2019 Jun; 38(23):4467-4479. PubMed ID: 30755732
[TBL] [Abstract][Full Text] [Related]
2. Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus.
Uchida H; Marzulli M; Nakano K; Goins WF; Chan J; Hong CS; Mazzacurati L; Yoo JY; Haseley A; Nakashima H; Baek H; Kwon H; Kumagai I; Kuroki M; Kaur B; Chiocca EA; Grandi P; Cohen JB; Glorioso JC
Mol Ther; 2013 Mar; 21(3):561-9. PubMed ID: 23070115
[TBL] [Abstract][Full Text] [Related]
3. Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma.
Wirsching HG; Zhang H; Szulzewsky F; Arora S; Grandi P; Cimino PJ; Amankulor N; Campbell JS; McFerrin L; Pattwell SS; Ene C; Hicks A; Ball M; Yan J; Zhang J; Kumasaka D; Pierce RH; Weller M; Finer M; Quéva C; Glorioso JC; Houghton AM; Holland EC
JCI Insight; 2019 Jul; 4(13):. PubMed ID: 31292299
[TBL] [Abstract][Full Text] [Related]
4. A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
Leoni V; Gatta V; Casiraghi C; Nicosia A; Petrovic B; Campadelli-Fiume G
J Virol; 2017 May; 91(10):. PubMed ID: 28250120
[TBL] [Abstract][Full Text] [Related]
5. Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.
Leoni V; Gatta V; Palladini A; Nicoletti G; Ranieri D; Dall'Ora M; Grosso V; Rossi M; Alviano F; Bonsi L; Nanni P; Lollini PL; Campadelli-Fiume G
Oncotarget; 2015 Oct; 6(33):34774-87. PubMed ID: 26430966
[TBL] [Abstract][Full Text] [Related]
6. A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors.
Leoni V; Vannini A; Gatta V; Rambaldi J; Sanapo M; Barboni C; Zaghini A; Nanni P; Lollini PL; Casiraghi C; Campadelli-Fiume G
PLoS Pathog; 2018 Aug; 14(8):e1007209. PubMed ID: 30080893
[TBL] [Abstract][Full Text] [Related]
7. Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma.
Appolloni I; Alessandrini F; Menotti L; Avitabile E; Marubbi D; Piga N; Ceresa D; Piaggio F; Campadelli-Fiume G; Malatesta P
Viruses; 2021 Aug; 13(9):. PubMed ID: 34578259
[TBL] [Abstract][Full Text] [Related]
8. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
[TBL] [Abstract][Full Text] [Related]
9. Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma.
Gambini E; Reisoli E; Appolloni I; Gatta V; Campadelli-Fiume G; Menotti L; Malatesta P
Mol Ther; 2012 May; 20(5):994-1001. PubMed ID: 22354378
[TBL] [Abstract][Full Text] [Related]
10. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
11. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.
Cheema TA; Wakimoto H; Fecci PE; Ning J; Kuroda T; Jeyaretna DS; Martuza RL; Rabkin SD
Proc Natl Acad Sci U S A; 2013 Jul; 110(29):12006-11. PubMed ID: 23754388
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.
Saha D; Martuza RL; Rabkin SD
Immunotherapy; 2018 Jul; 10(9):779-786. PubMed ID: 30008259
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice.
Reisoli E; Gambini E; Appolloni I; Gatta V; Barilari M; Menotti L; Malatesta P
Cancer Gene Ther; 2012 Nov; 19(11):788-95. PubMed ID: 22996742
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma.
Martikainen M; Niittykoski M; von und zu Fraunberg M; Immonen A; Koponen S; van Geenen M; Vähä-Koskela M; Ylösmäki E; Jääskeläinen JE; Saksela K; Hinkkanen A
J Virol; 2015 Oct; 89(20):10637-47. PubMed ID: 26269187
[TBL] [Abstract][Full Text] [Related]
16. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.
Panagioti E; Kurokawa C; Viker K; Ammayappan A; Anderson SK; Sotiriou S; Chatzopoulos K; Ayasoufi K; Johnson AJ; Iankov ID; Galanis E
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34196308
[TBL] [Abstract][Full Text] [Related]
17. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H
Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516
[TBL] [Abstract][Full Text] [Related]
18. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
19. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.
Wakimoto H; Kesari S; Farrell CJ; Curry WT; Zaupa C; Aghi M; Kuroda T; Stemmer-Rachamimov A; Shah K; Liu TC; Jeyaretna DS; Debasitis J; Pruszak J; Martuza RL; Rabkin SD
Cancer Res; 2009 Apr; 69(8):3472-81. PubMed ID: 19351838
[TBL] [Abstract][Full Text] [Related]
20. Generation of a Novel Mesothelin-Targeted Oncolytic
Froechlich G; Gentile C; Infante L; Caiazza C; Pagano P; Scatigna S; Cotugno G; D'Alise AM; Lahm A; Scarselli E; Nicosia A; Mallardo M; Sasso E; Zambrano N
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33418877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]